Introduction
Joint wear can cause persistent pain and stiffness, and articular cartilage has a limited capacity to heal on its own. If you are weighing up options for a worn or damaged joint, understanding what a given treatment actually is — and what it is not — matters as much as any headline claim. This article explains the ChondroFiller injection, a non-surgical collagen-based procedure, and how it sits alongside traditional surgical approaches, with realistic expectations throughout.
Traditional Surgical Approaches
Cartilage problems have historically been managed with surgical procedures. Debridement removes loose or damaged tissue to reduce pain and mechanical irritation. Microfracture drills small holes into the subchondral bone to stimulate a healing response, aiming to encourage fibrocartilage to fill the defect. Both can ease symptoms in selected patients, but results vary and the recovery involved is that of a surgical procedure — theatre, anaesthetic, and a structured rehabilitation period. The repair tissue from microfracture is fibrocartilage rather than the hyaline cartilage native to joints, and published evidence suggests functional benefit may diminish over time in some cases.
More advanced surgical options for focal cartilage defects include osteochondral autograft transfer and autologous chondrocyte implantation. These are established techniques with their own indications, risks, and recovery requirements, and represent a different tier of surgical intervention.
The ChondroFiller Injection
ChondroFiller is a Class III CE-marked type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. It is cell-free (acellular): once placed into the joint it self-gels in three to five minutes and provides a porous scaffold that the body's own progenitor cells can migrate into, potentially supporting cartilage repair over time. CE marking and the published outcome and safety evidence belong to ChondroFiller as a device.
When delivered as the ChondroFiller injection, this is a non-surgical, ultrasound-guided outpatient procedure. There is no theatre, no incision and no general anaesthetic. The collagen gel is injected into the affected joint space, where it may settle over worn surfaces and add a protective, cushioning layer. Most people return to normal activities promptly. Because it is collagen-based it has biological potential, but it is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure or reversal of arthritis. Benefits vary between individuals and joints.
A Note on Liquid Cartilage
Liquid Cartilage is not another name for the ChondroFiller injection. Liquid Cartilage is the Lee Liquid Cartilage Protocol: a keyhole (arthroscopic) surgical procedure developed by Professor Paul Y. F. Lee that delivers the ChondroFiller scaffold alongside biological adjuncts — such as platelet-rich fibrin or plasma — and, where indicated, the patient's own mesenchymal stem cells from bone-marrow concentrate. It involves a theatre setting, anaesthetic, and a structured rehabilitation programme, and is suited to larger or load-bearing cartilage defects in joints such as the knee, hip, ankle and shoulder.
The distinction matters when comparing options. The ChondroFiller injection is non-surgical; Liquid Cartilage is genuine surgery. Both use the same underlying scaffold material, but they are different treatment pathways suited to different clinical situations.
How ChondroFiller Compares with Traditional Surgical Approaches
The fundamental difference between the ChondroFiller injection and traditional surgical procedures is that one is an injection and the others are operations. ChondroFiller does not remove or alter tissue, does not breach the bone plate, and does not require a recovery period comparable to arthroscopic or open surgery. This makes it relevant for patients who are either not suitable for or not ready to consider surgical intervention, or where a joint-preserving non-surgical option is clinically appropriate.
A 2023 study of an acellular collagen matrix injection for thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength (Corain et al., 2023), though responses vary between people and joints, and benefits cannot be guaranteed. The evidence base for ChondroFiller continues to develop across different joint locations.
Choosing the Right Pathway
The most appropriate option depends on the joint involved, the degree and pattern of wear, your overall health, activity level and treatment goals. Non-surgical injection, keyhole surgical intervention and traditional surgery each have distinct indications, and no single pathway suits every patient. Expert assessment helps you weigh these options with accurate information and realistic expectations.
At the London Cartilage Clinic, consultations with a specialist allow a thorough review of imaging and clinical history to establish which pathway — whether the ChondroFiller injection, the Liquid Cartilage surgical protocol, or another approach — is most appropriate for your situation.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- Microfracture and debridement are surgical procedures carried out in theatre under anaesthetic. ChondroFiller is a non-surgical, ultrasound-guided injection given as an outpatient. There is no incision, no bone preparation and no surgical recovery period. Microfracture also breaches the subchondral bone plate; ChondroFiller does not, which preserves future treatment options.
- No. The ChondroFiller injection is a non-surgical outpatient procedure. Liquid Cartilage is a keyhole surgical protocol — developed by Professor Paul Y. F. Lee — that delivers the ChondroFiller scaffold surgically, alongside biological adjuncts and, where indicated, the patient's own stem cells. They use the same scaffold material but are entirely different pathways suited to different clinical situations.
- Some patients report reductions in pain and improved joint function, though responses vary and no outcome can be guaranteed. The injection is best understood as a supportive, joint-preserving procedure rather than a curative treatment or reversal of arthritis. Clinical evidence, including a 2023 study in thumb-base osteoarthritis, supports cautious optimism for selected patients.
- Suitability depends on the joint, the nature and extent of cartilage wear, your overall health and activity goals. The injection tends to be most relevant for accessible joints and smaller or moderate lesions where a non-surgical approach is clinically appropriate. Advanced arthritis or certain joint conditions may not be suitable indications. A specialist assessment — including review of imaging — is needed to determine this for any individual.
- The range of available approaches — from non-surgical injection through keyhole surgery to traditional surgical procedures — each carry different implications for recovery, outcomes and future options. The right choice depends on your individual clinical picture. A specialist helps translate imaging and clinical findings into a realistic plan, ensuring that expectations are grounded in evidence rather than optimism alone.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
